Abstract: Devices for treating uterine bleeding. An actuator is configured to receive an input to deploy an intrauterine portion of the device to assume a larger outer profile within the uterus. The actuator may be coupled to a device body and configured to receive a pull input, a push input, or a twist input. The intrauterine portion may include flexible opposing members, rotatable tines, a segmented hook, an adjustable loop, or compressible foam. The intrauterine portion defines a lumen and suction ports configured to draw suction within the uterus. Indicia may be provided on the actuator to indicate an extent by which the intrauterine portion has been deployed within the uterus. An orientation of the actuator may correspond to a direction of deployment of the intrauterine portion. The device may include valves and an auxiliary suction source configured to provide suction with the device decoupled from a vacuum source.

Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.

Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.

Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.

Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.

Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.

Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.

Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.

Abstract: Various embodiments are directed to a computer implemented method for updating a policy that is enforced by a computer program. In one embodiment, a computer communicates, to a user, data regarding one or more decisions made by the program over a period of time according to a policy. Each decision is made on the particular policy in force at the time the decision is made. Policy data for the policy is stored in a machine readable format. The user feedback data indicative of feedback by the user regarding the one or more decisions is stored. The computer identifies and ranks one or more potential variations to the policy based on a score of an objective function for each potential variation. The computer communicates, to the user, one or more suggested modifications based on the ranking of the one or more potential variations to the policy. The computer modifies the policy data based on one or more selections by the user in response to the transmission of the one or more suggested modifications.